Macrophages and macular degeneration.
Year: 2014
Type: article
Abstract: Treatment of retinal diseases such as age-related macular degeneration (AMD), macular edema and occlusive vascular disease has benefitted greatly from basic and translational research. Understanding of the role of vascular endothelial growth factor (VEGF) led to the development of its inhibitors, which are now widely applied.1 In this issue of JOVR, Nourinia et al2 investigate a potentially new drug that may one day be used to prevent further progression of AMD when started at an early stage. Zoledronic acid belongs to the bisphosphonates, which were originally developed as inhibitors of a specific type of macrophages, the osteoclast,3 and are being used to treat bone-resorption by bone metastases or
Source: PubMed
Author: Martine J Jager
Institution: Leiden University Medical Center
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W164506981